1003株结核分枝杆菌临床分离株对利福平与利福布汀的耐药性研究
对1003株结核分枝杆菌临床分离株进行全基因组测序并测定两种利福霉素类药物的MIC,发现766株利福平耐药株中210株(27%)对利福布汀敏感,其中102株携带rpoB D435V突变。不一致耐药株携带D435V突变的可能性是双耐药株的17.2倍(OR 17.2,95%CI 10.5-27.9,P<10^-40)。体外D435V突变体对两种药物的IC50均升高,但程度低于S450L突变,提示利福布汀临界测试浓度可能需要修订。
要点
- 利福平耐药株中约27%对利福布汀敏感,多与rpoB D435V突变相关。
- D435V突变体外试验中升高两种利福霉素IC50,并非仅利福平耐药。
- 建议重新评估利福布汀药敏试验的临界浓度。
核心结论
- rpoB D435V突变可同时升高利福平和利福布汀的IC50,提示利福布汀临界测试浓度应修订。
研究设计与样本
- 对1003株结核分枝杆菌临床分离株进行全基因组测序,用7H10琼脂间接比例法测定两种药物MIC。
- 在实验室株中构建rpoB突变体,用alamarBlue还原法测定药敏。
主要发现
- 766株利福平耐药株中210株(27%)对利福布汀敏感,其中102株携带rpoB D435V突变。
- 不一致耐药株携带D435V突变的可能性是双耐药株的17.2倍(OR 17.2,95%CI 10.5-27.9,P<10^-40)。
- 体外D435V突变体对两种利福霉素的IC50均升高,但升高程度低于S450L突变体。
关键数值与推荐
- 利福平耐药株中利福布汀敏感比例为27%(210/766)。
- D435V突变与不一致耐药的OR为17.2(95%CI 10.5-27.9,P<10^-40)。
临床怎么用
- 对利福平耐药结核株应关注rpoB D435V突变,其可能对利福布汀也非敏感。
- 现有推荐利福布汀临界浓度可能需重新评估以指导临床用药。
局限性
- 体外突变体结果不能完全代表临床分离株的耐药表型。
- 研究未提供利福布汀临界浓度修订的具体数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Drug-resistant TB remains a public health challenge. Rifamycins are among the most potent anti-TB drugs. They are known to target the RpoB subunit of RNA polymerase; however, our understanding of how rifamycin resistance is genetically encoded remains incomplete. Here we investigated rpoB genetic diversity and cross-resistance between the two rifamycin drugs rifampicin and rifabutin. METHODS: We performed WGS of 1003 Mycobacterium tuberculosis clinical isolates and determined MICs of both rifamycin agents on 7H10 agar using the indirect proportion method. We generated rpoB mutants in a laboratory strain and measured their antibiotic susceptibility using the alamarBlue reduction assay. RESULTS: Of the 1003 isolates, 766 were rifampicin resistant and 210 (27%) of these were rifabutin susceptible; 102/210 isolates had the rpoB mutation D435V (Escherichia coli D516V). Isolates with discordant resistance were 17.2 times more likely to harbour a D435V mutation than those resistant to both agents (OR 17.2, 95% CI 10.5-27.9, P value <10-40). Compared with WT, the D435V in vitro mutant had an increased IC50 of both rifamycins; however, in both cases to a lesser degree than the S450L (E. coli S531L) mutation. CONCLUSIONS: The observation that the rpoB D435V mutation produces an increase in the IC50 of both drugs contrasts with findings from previous smaller studies that suggested that isolates with the D435V mutation remain rifabutin susceptible despite being rifampicin resistant. Our finding thus suggests that the recommended critical testing concentration for rifabutin should be revised.
引用
- Farhat MR, Sixsmith J, Calderon R, et al. Rifampicin and rifabutin resistance in 1003 Mycobacterium tuberculosis clinical isolates. J Antimicrob Chemother. 2019. PMID: 30793747. doi:10.1093/jac/dkz048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。